#Apellis Pharmaceuticals (APLS)

Apellis Pharmaceuticals Negative CHMP Opinion Apellis Pharmaceuticals ( APLS ) announced that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency has adopted a...

Apellis Pharmaceuticals Launch Update of SYFOVRE ® On October 5, 2023, Apellis Pharmaceuticals ( APLS ) provided an update on the launch of its product SYFOVRE® (pegcetacoplan injection) for geographi...

Prohost Letter #457 Discovering The Root Causes of Diseases   Biotech firms with solid scientific fundamentals are racing towards unveiling the root-causes of various diseases that have yet to be comp...

Apellis Pharmaceuticals Validation for Pegcetacoplan Apellis Pharmaceuticals ( APLS ) announced the receival of validation of its marketing applications by regulatory authorities in Canada, Australia,...

Apellis Pharmaceuticals Apellis Pharmaceuticals, Inc. ( APLS ) is a biopharma firm developing novel products for debilitating and life-threatening diseases. Currently, Apellis has two approved medicin...